Recent Representative Transactions

For Evofem Biosciences, Inc.

• $80 million common stock PIPE with Woodford Investment Management and PDL Biopharma, Inc.

• $100 million public offering underwritten by Morgan Stanley

• $50 million ATM managed by Piper Sandler & Co.

• Merger with Neothetics, Inc. (stock for stock)

• $25 million senior secured convertible note PIPE with Baker Bros. 

• $1 million preferred stock PIPE with Keystone Capital

• $25 million unsecured convertible note PIPE with Adjuvant Global Health Technology Fund

• $13.5 million registered direct offering conducted on a best efforts basis by Piper Sandler & Co.

• $24 million public offering underwritten by H.C. Wainwright

For GRI Bio, Inc.

• $12.5 million common stock PIPE with warrants with Altium Growth Fund

• Merger with Vallon Pharmaceuticals (stock for stock)

• $5 million public offering of common stock, pre-funded warrants and warrants to purchase preferred stock underwritten by AGP

• ATM managed by H.C. Wainwright

For Wickr, Inc.

• $8.3 million Series B-2 preferred stock financing led by Alsop Louie and Breyer Capital

• $5 million Series C preferred stock financing led by Merlin International Inc.

• $5 million venture debt financing with SVB

• Merger with Net Power and Light (stock for stock)

Other Recent Financing Transactions

• $3 million convertible note financing of Avenzoar Pharmaceuticals led by Ally Capital Holdings

• $2 million Series A Preferred Stock financing of Curvo Labs, Inc. led by Snake Run Capital and Indiana 21st Century Fund

• $18 million Series A Preferred Stock financing of FAScinate Therapeutics, Inc. led by Kainos Medicine and TWI IP Commercialization Fund and The Wells Doctors Healthcare Fund

• $2 million convertible note financing of Hollywood Glow Girls

• $2 million convertible note financing of Injury AI, Inc.

• $1 million convertible note financing of Regencor, Inc.

Other Recent M&A Transactions

• Curvo Labs, Inc. stock purchase of Mendenhal Associates (cash consideration)

• Curvo Labs, Inc. stock purchase of Strategic Healthcare (cash consideration)

• Evofem, Inc.’s asset purchase of Cosmederm, Inc. (cash consideration)

• Encore Sports asset sale to Decade Sports (cash consideration)

• Evanoa Bioscience, Inc. asset acquisition of Evolugate LLC (stock consideration)

• Evanoa Bioscience, Inc. asset acquisition of Biotork LLC (stock consideration)

Commercial Agreements

• License Agreement between NeptuneBio, Inc. and Mayo Clinic

• Development Agreement between Evanoa Bioscience and Aldevron

• Multiple Consulting Agreement and Employment Agreements

• License Agreement between Avenzoar Pharmaceuticals and Cedars-Sinai

• Development Agreement between Biotork LLC and Lallemand/Mascoma

• Joint Venture Agreement between Caelum Resources, Inc. and CFS Holdings Private Limited Zimbabwe

• Multiple SAAS Agreements for Curvo Labs, Inc. and Wickr Inc.

• License Agreement between FAScinate Therapeutics and Kainos Medicine

• License Agreement between InVaMet and Virginia Commonwealth

• License Agreement between ILCT and Virginia Commonwealth